PMC7154000_01
Whole-body PET-CT findings. PET-CT imagings showed abnormal increase of glucose metabolism in the lower lobe of the right lung (A), in the liver (B) and in both adrenal regions (C).
OTT-13-3039-g0001.jpg
PMC7154000_01_OTT-13-3039-g0001.jpg
F0001
A positron emission tomography computed tomography (PET-CT) was obtained one month later, which demonstrated abnormal increase of glucose metabolism in the lower lobe of the right lung, considered as malignant tumor; abnormal high glucose metabolism in the liver, abnormal increase of glucose metabolism and soft tissue density in both adrenal regions, considered as metastasis (Figure 1).
CT imaging of the NSCLC patient. CT imaging showed the lung focus was obviously shrinked after treated with gefitinib (A). The masses in lung were lager than before (B). The lung focus was obviously shrinked again after treated by gefitinib with kazzinib (C). Recurrent progress of lesions (D). The masses shrinked again after treated by immunotherapy combined with chemotherapy (E). The lesion shrank again in recently (F).
OTT-13-3039-g0002.jpg
PMC7154000_01_OTT-13-3039-g0002.jpg
F0002
Re-examination of chest CT showed the lung focus was obviously shrinked (Figure 2A). However, the masses in lung were lager than before in April 23, 2018 (Figure 2B). The lung CT showed the lung focus was obviously shrinked again in June 06, 2018 (Figure 2C). Moreover, Re-examination of chest CT showed recurrent progress of lesions in December 18, 2018 (Figure 2D). CT scan revealed the clinical response with shrinkage of over 30% of the lung lesion on February 27, 2019 (Figure 2E). Examination of chest CT showed the patient was PR on June 26, 2019 (Figure 2F).
The masses in liver before and after treatment. The masses in liver of upper abdomen MRI before any treatment (A) and after immunotherapy combined with chemotherapy (B).
OTT-13-3039-g0003.jpg
PMC7154000_01_OTT-13-3039-g0003.jpg
F0003
The masses in liver were also significantly smaller than before (Figure 3).
Timeline of events since the diagnosis and summary of administered treatments.
OTT-13-3039-g0004.jpg
PMC7154000_01_OTT-13-3039-g0004.jpg
F0004
The diagnosis and administered treatments of this NSCLC patient were summarized (Figure 4).